Document is current
Any future updates will be listed below
-
Authors
Ruckert, Mariana T.
Walsh, R. McKinnon
Bye, Bailey A.
Eades, Austin E.
Yan, Wei
Bednar, Filip
Shi, Jiaqi
Lasse Opsahl, Emily L.
Pasca di Magliano, Marina
Lyssiotis, Costas A.
VanSaun, Michael N.
Silveira, Vanessa S.
-
Funding
Funding for this research was provided by:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP 2015/10694-5, FAPESP 2015/10694-5)
Fulbright Association
National Cancer Institute (R37CA262209, R37CA237421, R01CA248160, R01CA244931)
Cancer Center, University of Kansas
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (001)
- License Information
-
More Information
Article History
Received: 24 January 2025
Accepted: 21 July 2025
First Online: 30 September 2025
Declarations
:
: In the past three years, CAL has consulted for Astellas Pharmaceuticals, Odyssey Therapeutics, Third Rock Ventures, and T-Knife Therapeutics, and is an inventor on patents pertaining to Kras regulated metabolic pathways, redox control pathways in pancreatic cancer, and targeting the GOT1-ME1 pathway as a therapeutic approach (US Patent No: 2015126580-A1, 05/07/2015; US Patent No: 20190136238, 05/09/2019; International Patent No: WO2013177426-A2, 04/23/2015). All the remaining authors declare no conflict of interest.
: Experiments involving mice were approved by the Ethics Committee on Animal Research at Ribeirao Preto Medical School, University of São Paulo (protocol# 016/2018), and conducted in accordance with the Guidelines of the Brazilian College of Animal Experimentation. Experiments performed at the Massachusetts General Hospital and the University of Kansas Medical Center were subjected to IACUC protocols (2005N000148 and 2019N000116; and 22-02-226, respectively) and were conducted according to the ARRIVE guidelines.
: This study was supported by São Paulo Research Foundation (FAPESP 2015/10694-5) granted to VSS. MTR was supported by CAPES Foundation (Finance Code 001) and Fulbright Association. JS is supported in part by the National Cancer Institute of the National Institutes of Health under award number R37CA262209. MVS received funds from the University of Kansas Cancer Center. CAL was supported by the NCI (R37CA237421, R01CA248160, and R01CA244931).
